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Background: In current practice, patients with chronic pancreatitis undergo surgical intervention in a late stage of
the disease, when conservative treatment and endoscopic interventions have failed. Recent evidence suggests that
surgical intervention early on in the disease benefits patients in terms of better pain control and preservation of
pancreatic function. Therefore, we designed a randomized controlled trial to evaluate the benefits, risks and costs of
early surgical intervention compared to the current stepwise practice for chronic pancreatitis.
Methods/design: The ESCAPE trial is a randomized controlled, parallel, superiority multicenter trial. Patients with
chronic pancreatitis, a dilated pancreatic duct (≥ 5 mm) and moderate pain and/or frequent flare-ups will be
registered and followed monthly as potential candidates for the trial. When a registered patient meets the
randomization criteria (i.e. need for opioid analgesics) the patient will be randomized to either early surgical
intervention (group A) or optimal current step-up practice (group B). An expert panel of chronic pancreatitis
specialists will oversee the assessment of eligibility and ensure that allocation to either treatment arm is possible.
Patients in group A will undergo pancreaticojejunostomy or a Frey-procedure in case of an enlarged pancreatic
head (≥ 4 cm). Patients in group B will undergo a step-up practice of optimal medical treatment, if needed
followed by endoscopic interventions, and if needed followed by surgery, according to predefined criteria. Primary
outcome is pain assessed with the Izbicki pain score during a follow-up of 18 months. Secondary outcomes include
complications, mortality, total direct and indirect costs, quality of life, pancreatic insufficiency, alternative pain scales,
length of hospital admission, number of interventions and pancreatitis flare-ups. For the sample size calculation we
defined a minimal clinically relevant difference in the primary endpoint as a difference of at least 15 points on the
Izbicki pain score during follow-up. To detect this difference a total of 88 patients will be randomized (alpha 0.05,
power 90%, drop-out 10%).
Discussion: The ESCAPE trial will investigate whether early surgery in chronic pancreatitis is beneficial in terms of
pain relief, pancreatic function and quality of life, compared with current step-up practice.
Trial registration: ISRCTN: ISRCTN45877994
Keywords: Chronic pancreatitis, Pain, Surgical management, Surgery, Endoscopic treatment, Endoscopy, ERCP,
Opioid, Pancreaticojejunostomy, Frey procedure* Correspondence: m.a.boermeester@amc.uva.nl
1Department of Surgery, Academic Medical Center Amsterdam, PO 22660,
1100 DD, Amsterdam, the Netherlands
Full list of author information is available at the end of the article
© 2013 Ahmed Ali et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Ahmed Ali et al. BMC Gastroenterology 2013, 13:49 Page 2 of 14
http://www.biomedcentral.com/1471-230X/13/49Background
In patients with chronic pancreatitis (CP), the most im-
portant clinical problem is the management of pain,
which often occurs daily and is disabling [1,2]. CP is also
associated with pancreatic insufficiency, both endocrine
and exocrine [3,4], which develops in 50% and 80% of
patients within 5 years, respectively. CP is related to sev-
eral causative factors, most notably alcohol toxicity.
Other factors such as genetics, anatomic abnormalities
and autoimmunity also play a role [5].
In current practice, patients with CP are managed by a
conservative step-up practice. The first step is medical
management, ranging from pancreatic enzymes and mild
analgesics to opioids. When medical management fails,
the next step is usually endoscopic intervention. Surgical
intervention is kept as an option of last resort when other
treatments have failed and the severity of disease has in-
creased substantially and pain becomes unmanageable
[6,7]. This approach is based on the so called ‘burnout hy-
pothesis’, assuming that CP is a ‘self-limiting’ disease in
which pain will ultimately resolve spontaneously due to
progressive parenchymal destruction of the pancreas [3].
Many reports have questioned the validity of this hypoth-
esis, including the group that first introduced it [4,8]. The
main argument against the burnout hypothesis is the long
time it takes for pain to subside; e.g. after 5 years of the
onset of the disease about 60% of the patients will still ex-
perience substantial pain, and that in many reports
complete insufficiency (‘burnout’) of the gland does not
guarantee pain relief [4,8].
As an alternative to the current conservative step-up
practice, there is emerging evidence to suggest that
surgery early in the clinical course of CP is beneficial in
terms of pain control and pancreatic function. First,
pathophysiological studies of pain in CP have shown that
prolonged periods of pain are associated with peripheral
and central nerve sensitization. Consequently, a self-
perpetuating pain state develops, which is very difficult
to reverse and manage [9]. Secondly, experimental and
clinical studies suggest that early surgical intervention
can mitigate disease progression. In an experimental
model of early versus late surgical drainage for CP
in piglets, we have previously demonstrated that early
surgery resulted in less histological cell damage and
better exocrine pancreatic function [10]. Clinically, two
observational cohort studies have shown that surgical
interventions, especially drainage procedures, have the
potential to delay the progressive loss of pancreatic func-
tion in CP patients [11-13]. We recently also performed
an observational study that supports the hypothesis
that longstanding disease is associated with poor pain
control after surgical intervention. In 266 consecutive
patients undergoing an operation for CP we observed
that surgery after 3 years of onset of symptoms wasindependently associated with worsened pain outcome
and increased rates of endocrine pancreatic insufficiency.
Additionally, preoperative use of opioids (indicative of
severity of disease and time-delay to surgery) were sig-
nificantly associated with bad outcome of surgery in
terms of pain control [14].
Finally, in a small pilot randomized trial, 32 patients
with early stage CP and dilated pancreatic duct were
randomized between early surgical drainage and a con-
servative approach [13,15]. Substantial pain relief was
observed in 16/17 (94%) patients in the surgical group
compared to 2/15 (13%) patients in the conservative
group. New onset endocrine and exocrine pancreatic in-
sufficiency were respectively observed in 2/13 (15%) and
1/15 (7%) in the early surgical group compared to 10/12
(83%) and 11/14 (79%) in the conservative group [13].
Despite the evidence suggesting a benefit of early sur-
gery, most patients with chronic pancreatitis are not
managed by this approach in current practice. Therefore,
the Dutch Pancreatitis Study Group designed a random-
ized controlled multicenter trial to evaluate the benefits,
risks and costs of early surgical intervention: the Early
Surgery versus Optimal Current Step-up Practice for
Chronic Pancreatitis (ESCAPE) – trial.
Methods
Study design
The ESCAPE trial is an open label randomized con-
trolled, parallel, superiority multicenter trial.
Objectives
Study hypothesis
We hypothesize that early surgery can relieve pain early
in the disease course of chronic pancreatitis. This will,
consequently, improve patients’ health status, reduce
health demand and costs and increase quality of life and
social functioning.
Research questions
 Primary study question: does early surgery, as
compared to the current optimal step-up practice,
provide better pain control in patients with CP and
a dilated pancreatic duct?
 Secondary study question: What is the impact of
early surgery in these patients in terms of severe
complications, mortality, quality of life, costs,
endocrine and exocrine pancreatic insufficiency and
other clinical relevant outcomes?
Study population
Patients with CP meeting the inclusion criteria for regis-
tration will be asked to participate in the study (registra-
tion informed consent). Consenting patients will be
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When a registered patient meets the randomization
criterion he/she will be enrolled in the study after expli-
cit informed consent. An expert panel of CP specialists
(gastroenterologists, surgeons and radiologists) will
oversee the assessment of eligibility and will ensure that
allocation to either treatment arm is possible prior to
randomization. Patients will be recruited from 24 hos-
pitals of the Dutch Pancreatitis Study Group.
Inclusion criteria
 Age > 18 years
 Confirmed CP: according to the following criteria
(adapted from the M-ANNHEIM diagnostic criteria
[16]):
▪ typical clinical history of chronic pancreatitis
(i.e. recurrent pancreatitis or abdominal pain), and:
▪ one or more of the following additional criteria
for the diagnosis of CP:
1. Pancreatic calcifications on CT or MRI imaging.
2. Moderate or marked ductal lesions (according to
the Cambridge classification) on endoscopic
retrograde cholangiopancreatography (ERCP) or
magnetic resonance cholangiopancreatography
(MRCP) imaging.
3. Marked and persistent exocrine insufficiency
(defined as: a. pancreatic steatorrhea clearly
relieved by enzyme supplementation, and/or b.
fecal elastase levels of ≤ 200 micro gram/gram).
 Dilated pancreatic duct: dilated pancreatic duct
of ≥ 5 mm, with or without enlargement of the
pancreatic head [17].
 Presence of moderate, non-debilitating pain. This
will be defined as chronic or recurrent abdominal
pain sufficiently relieved with non-opioid analgesics.
Randomization criteria (after fulfilling inclusion criteria for
registration)
Patients will be eligible for randomization if one of the
following criteria is met:
 In patients with chronic abdominal pain related to
chronic pancreatitis: a need to upgrade pain
medication from non-opioids to opioid analgesics
(opioids needed at least 3 days per week) and
persistently needed for at least 2 weeks.
 In patients with recurrent flare-ups interspaced with
pain-free intervals: flare-ups that have occurred at
least 3 times during one year (i.e. 12 months), with
each flare-up fulfilling the following criteria:
▪ duration of at least 7 consecutive days;
▪ necessitate opioid use during flare-up;
▪ impairment of daily activities.Informed consent must also be acquired for randomization.
Exclusion criteria
 History of prolonged need of opioids: history for
need for strong opioids for CP for a total period
over 2 months or a history for need for weak
opioids for CP for a total period of 6 months in the
last 2 years. The following medications are
considered weak opioids: codeine,
dextropropoxyphene, dihydrocodeine, tramadol and
partial agonists of morphine (e.g. pentazocine,
butorphanol, nalbuphine).
 Previous pancreatic surgery
 Previous endoscopic dilatation or stenting of the
pancreatic duct
 Episode of biliary obstruction in the previous
2 months (defined as jaundice or bilirubin levels ≥
25 micromol / L) or the presence of a stent in the
common bile duct
 Autoimmune pancreatitis (including elevated levels
of gamma-globulins (IgG))
 Stones and strictures exclusively located in the tail
of the pancreas (i.e. to the left of the vertebra) with
relatively normal pancreatic head and corpus
(Figure 1).
 Fully impacted stones casting the entire main
pancreatic duct (from head to tail) and possibly side
branches (Figure 2).
 Suspected or confirmed pancreatic malignancy
 Life expectancy of < 1 year for any reason
 Presence of duodenal obstruction necessitating
surgery, as judged by the expert panel
 Presence of a pseudocyst larger than 6 cm
necessitating intervention, as judged by the
expert panel
 Contra-indications for surgery, as judged by the
expert panel (e.g. American Society of
Anesthesiology class IV, severe portal hypertension
due to occluded portal vein)
 Pregnancy
Study interventions
Patients will be randomly allocated to either early surgi-
cal intervention (group A) or step-up practice (group B).
Figure 3 illustrates the management strategies in both
intervention arms.
Group A) early surgical intervention
The main aim of the surgical intervention will be surgi-
cal drainage of the dilated pancreatic duct. According to
the size of the pancreatic head on the preoperative im-
aging (CT and MRI or ERCP), the following operation
will be performed:
Figure 1 CT scan depicting stones and strictures exclusively located in the tail of the pancreas.
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surgical drainage of the pancreatic duct by a
pancreaticojejunostomy.
 In case of an enlarged pancreatic head (≥ 4 cm):
surgical drainage of the pancreatic duct and a
duodenal-preserving pancreatic head resection
(a Frey procedure).
Surgery will be performed within 6 weeks after
randomization by an experienced pancreatic surgeon.
Experience is defined as having previously performed at
least 25 pancreatic operations for chronic pancreatitis,
not including pancreatic cyst drainage.
Pancreaticojejunostomy
A pancreaticojejunostomy is performed as described by
Partington and Rochelle [18]. The pancreatic duct is in-
cised over its full length, from the tip of the tail to 2 cm
from the ampulla. For removal of stones a V-shaped in-
cision of the head may be necessary. The length of the
anastomosis will be measured. Intra-operative photo-
graphs of the full length opened pancreatic duct will
be taken to ensure that a uniform procedure was
performed. If no pancreatic head enlargement is seen onFigure 2 CT scan depicting fully impacted stones casting the entire mpreoperative imaging, but during the operation a mark-
edly enlarged pancreatic head is found (≥ 4 cm), a Frey
procedure is performed (see below).
Frey procedure
A duodenal-preserving resection of the pancreatic head,
combined with a longitudinal pancreaticojejunostomy, is
performed according to the technique described by Frey
and Smith [19]. For the pancreaticojejunostomy, the pan-
creatic duct is incised over the full length (about 2 cm from
the distal end of the tail to 2 cm from the ampulla. For re-
construction, one longitudinal pancreatojejunostomy is
constructed, draining the resection cavity of the head
and the full-length opened pancreatic duct. A biliodigestive
anastomosis is performed in case of stenosis of the
intrapancreatic segment of the common bile duct which
cannot be decompressed by resecting the circumferential
fibrous tissue.
Group B) optimal current step-up practice
Patients randomized to the optimal current step-up
practice will undergo the following stepwise treatment
strategy as formulated by consensus of the Dutch
Chronic Pancreatitis Expert Panel:ain pancreatic duct from head (A) to tail (B).
CP patients with dilated pancreatic duct  
(≥ 5mm) and moderate pain 
REGISTRATION & FOLLOW-UP 
Group A 
Early surgical intervention 
Group B 
Optimal Current Step-up Practice 
Patient meeting the randomization criteria  
(newly developed need for opioid analgesics)  
RANDOMIZATION
Enlarged pancreatic head (≥ 4cm) 
Yes 
Frey procedure Pancreatico- 
jejunostomy 
No 
Step 1. Optimal medical management 
− Optimal pain medication (WHO pain 
ladder) 
− Co-medication for neuropathic pain 
− Dietary advice 
− Management of pancreatic insufficiency 
Failure of medical management 
− Unsatisfactory pain control, or  
− Clinically unacceptable side-effects 
Step 2. Endoscopic intervention 
ERCP with sphincterotomy, and 
− Dilatation of strictures (if necessary) 
− Placement of pancreatic duct stent 
− ESWL for large intraductal stones 
Failure of endoscopic treatment 
− Unsatisfactory pain control 
Step 3. Surgical intervention
(as in group A) 
Figure 3 Flow-diagram of study intervention arms in the ESCAPE-trial. CP: chronic pancreatitis. ERCP: Endoscopic Retrograde
Cholangiopancreaticography; ESWL: extracorporeal shock-wave lithotripsy. WHO: World Health Organization.
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Optimal pain control is attempted through the pain
management guidelines as described below. A pain spe-
cialist and dietician will be consulted to optimize med-
ical management. As long as pain control is achieved,
the patient will remain in step 1.
Guidelines for this medical management are [20,21]:
– Optimal pain medication according to the World
Health Organization pain ladder, as follows:○ Non-opioid medication: paracetamol (up to 4
daily doses of 1000 mg), or non-steroidal anti-
inflammatory drugs (NSAIDs) (up to 3 daily
doses of 75 mg of diclofenac or equivalent dose
of other NSAIDs). When NSAIDs are used for
a prolonged period of time, appropriate gastric
protection should be given.
○ Weak opioids: tramadol (start: 3 daily doses of
50 mg used when needed; up to 4 daily doses
of 100 mg).
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etc. Choice of medication and dose determined
by treating physician (start morfine retard 2
daily doses of 10 mg or equivalent dose of
another opioid; subsequent titration of dose
should be guided by pain levels, development of
tolerance and side-effects).The type and dose of medication will be decided at the
discretion of the treating physician and based on the
clinical situation of the patient. As a guideline the phys-
ician should aim to maintain the pain VAS of the patient
below a score of 4.
– Co-medication for neuropathic pain: in consultation
with the pain specialist starting of one of the
following co-medications for neuropathic pain is
allowed.
○ Pregabaline (start: 2 daily doses of 75 mg;
maximal dose: 2 daily doses of 300 mg).
○ Gabapentine (start: gradual increase over 3 days
to a 3 daily dose of 300 mg; maximal dose: 3
daily doses of 1200 mg).
○ Amitryptyline (start: 25 mg per day before
sleeping; maximal dose: 100 mg per day before
sleeping).
– Dietary advice: patients will be referred for
consultation with a dietician for analysis of
nutritional status and starting of any necessary
dietary program.
– Screening and management of pancreatic
insufficiency at baseline:
○ Endocrine insufficiency will be screened by
glucose level measurement. If endocrine
insufficiency is established, the patient will be
referred to a specialized internal medicine
physician for management.
○ Exocrine insufficiency will be defined as
presence of steatorrhoea, or fecal elastase levels
at baseline of < 200 microgram/gram (measured
in all patients as part of the study protocol –
see ‘Outcome measures’). Patients with exocrine
insufficiency will be treated with pancreatic
enzyme substitution (start: equivalent to
25,000–50,000 FIP-E lipase with main meal, and
10,000–25,000 FIP-E lipase with in-between
snacks; maximal dose: 10,000 FIP-E lipase/kg
body weight per day).
Failure of medical management (failure of step 1)
If symptoms become intractable to medical management
for a prolonged period of time despite adequate adjust-
ment of medication, medical management is considered
to have failed. This is defined as one of the following:– Unsatisfactory pain control: defined as a VAS pain
score > 4 in three follow-up moments (patients will
be followed once every 2 weeks, see section ‘Data
collection and follow-up’) despite adequate
adjustment of medication.
– If achieving satisfactory pain control is associated
with clinically unacceptable side-effects, the
medication should be discontinued. Such side effects
might include sedation, nausea, vomiting,
constipation or itching.
Step 2. Endoscopic intervention
Patients with failed medical management will be referred
for endoscopic intervention by an experienced endosco-
pist. Experience will be defined as having performed at
least 50 therapeutic endoscopic interventions for chronic
pancreatitis. The goal of the initial endoscopic interven-
tion will be to drain the pancreatic duct by means of a
pancreatic stent. At the end of endoscopic treatment of
strictures and stones, as described below, adequate alle-
viation of pain should have been achieved.
1. Stone removal: in the absence of large (diameter
≥7 mm) intraductal stones in the pancreatic duct,
patients will undergo an ERCP for stone removal.
After sphincterotomy, a complete stone removal will
be attempted. If stone removal is incomplete one or
more pancreatic stents will be inserted and further
stone removal will be attempted at the following
ERCP. If large intraductal stones (diameter of ≥ 7 mm)
are identified in the pancreatic duct on pre-
intervention imaging studies, the patient will first
undergo extracorporeal shock-wave lithotripsy
(ESWL). After lithotripsy, stone fragments will be
removed during the subsequent endoscopic
intervention.
2. Strictures and stent placement: the decision for need
of stricture dilation, with either a balloon catheter or
a Soehendra catheter, will be made by the treating
endoscopist. If strictures are present, a stent will be
inserted in the pancreatic duct.
3. Progressive stenting: if a stent has been inserted,
endoscopic treatment will be considered technically
successful. From this point, the patient must have
adequate pain control (with or without pain
medication) in order to continue with endoscopic
treatment (see section “Failure of endoscopic
intervention”). Continuation of endoscopic
treatment means the patients will undergo an
elective endoscopic pancreatogram every 4 months.
When complete runoff of contrast material is
observed after removal of the stent and an
extraction balloon can be passed through the
pancreatic duct, endoscopic treatment is considered
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strictures will be treated by repeated endoscopic
dilations and sequential insertion of new stents for a
maximal period of 1 year, after which stenting must
be stopped.
Failure of endoscopic intervention (failure of step 2)
Failure of endoscopic intervention is defined as:
– Persistent pain after 12 weeks of endoscopic therapy
(assessed from 8 weeks onwards after the start of
endoscopic therapy): defined as a VAS pain score > 4
in at least three out of four follow-up moments (with
or without pain medication). When no endoscopic
treatment was found to be possible after attempting
by a skilled endoscopist and pain persists, failure of
endoscopic intervention will also be a fact.
Step 3. Surgical intervention
If endoscopic intervention fails, the third en last step will
be surgical intervention. Surgical intervention will be
done as described for group A.
Outcome measures
Primary outcome
The primary clinical outcome is the degree of pain as
assessed by the Izbicki pain score at 2 weeks intervals dur-
ing the follow-up period of 18 months. The Izbicki pain
score is a validated pain score specifically designed for
chronic pancreatitis [17,22]. It consists of four questions
regarding frequency of pain, intensity of pain (VAS score),
use of analgesics, and disease-related inability to work.
Based on these question a pain score can be calculated
ranging from 0 (no pain) to 100 (severe, debilitating pain).
Secondary outcome
Secondary outcomes are:
 Severe complications related to disease progression,
or endoscopic and surgical interventions (see Table 1
for definitions):
○ Mortality (all-cause)
○ Disease progression: development of
pseudocysts, pancreatic insufficiency (endocrine
or exocrine), duodenum obstruction, chronic
use of opioids (defined as need for opioids for a
period > 6 months), hospital admissions for CP
up flares.
○ Endoscopic intervention: (acute) pancreatitis
flare-up, cholangitis, acute cholecystitis,
retroperitioneal or bowel perforation,
haemorrhage.
○ Surgical intervention: anastomotic leakage,
bleeding, sepsis, intra-abdominal abscesses,burst abdomen, pneumonia, severe wound
infection (requiring prolonged hospital stay),
severe delayed gastric emptying (requiring >
10 days of nasogastric intubation or inability to
tolerate solid diet on or after the 14th
postoperative day), any relaparotomy for other
reasons.
 Quality of life: assessed by the validated short form
36 (SF-36) and the EQ-5D questionnaires [23,24].
 Total direct and indirect costs
 Endocrine pancreatic insufficiency: determined by
use of anti-diabetic medication or abnormal serum
glucose levels (fasting serum glucose levels >
6.0 mmol/L in capillary blood, or > 6.9 mmol/L in
venous plasma at two different days) [25].
 Exocrine pancreatic insufficiency: determined by
fecal elastase levels (< 200 μg/g).
 Additional pain measurements: due to the
heterogeneity in reporting of pain in previous trials,
and in order for the results of this trial to be
comparable with other studies, the following
additional measures of pain will be reported as well:
○ Proportion of patients with complete and
partial pain relief at end of follow-up, defined as
follows [17]:
▪ Complete pain relief: an Izbicki pain score ≤ 10
points
▪ Partial pain relief: a decrease of >50% from
baseline in the Izbicki score with a final score
>10 points.
○ Visual analogue score (VAS) for pain: measured
as part of the Izbicki score.
○ Büchler pain score: alternative pain measure
based on the Izbicki questionnaire, and
calculated by the multiplication of two of the
four items of the Izbicki questionnaire (i.e. pain
frequency and pain intensity) [26].
 Number and duration of hospital admissions during
study period.
 Number of performed interventions: total number
of endoscopic and surgical interventions, including
initial intervention.
 Number of pancreatitis flare-ups during the study period.
Randomization
Randomization will be performed using a central auto-
mated online assignment system ensuring random gen-
eration of allocation and concealment of allocation. Only
after the expert panel ensures a patient fulfills the eligi-
bility criteria, the patient’s information is entered into
the central online randomization module, which subse-
quently allocates the patient to one of the two groups.
Block randomisation with varying block size (2, 4 or 6)
Table 1 Definitions of complications
Complications Definition
Pseudocysts Fluid-filled collection in the pancreas without epithelial cover proven by CT.
Duodenum obstruction Clinical symptoms suggestive of duodenal obstruction (retention, nausea, vomiting) and imaging evidence of
duodenum obstruction by the pancreas.
Chronic use of opioids Daily need for strong opioids for a period > 6 months.
(Acute) pancreatitis flare-up Episode of upper abdominal pain requiring hospitalization with either increased amylase (>3 normal level) or
typical upper abdominal pain recognized by patient from previous episodes.
Cholangitis 1) Body temperature > 38.5°C and 2) Bilirubin > 20 μmol/L and/ or common bile duct of > 8 mm for age ≤
75 years or > 10 mm for age > 75 years on abdominal ultrasound or CT.
Acute cholecystitis 1) Local signs of inflammation (Murphy’s sign, right upper quadrant mass/pain/tenderness), 2) Systemic signs of
inflammation (Fever, elevated CRP, elevated WBC) and 3) Gallstones on abdominal ultrasound.
Perforation Retroperitoneal or bowel-wall perforation documented by any radiographic technique.
Anastomotic leakage:
Pancreaticojejunostomy
High amylase level (>3 times serum amylase) in the abdominal drain fluid, or pancreatic leakage proven by
imaging or at relaparotomy, often but not necessarily in combination with one or more clinical signs
(abdominal pain, peritoneal tenderness, temperature above 38.5°C or WBC above 15 X 109/l).
Anastomotic leakage: biliary
leakage
Bilirubin in abdominal drain or dehiscence found at laparotomy, often but not necessarily in combination with
one or more clinical signs (abdominal pain, peritoneal tenderness, temperature above 38.5°C or WBC above
15 x 109/l).
Bleeding/ Hemorrhage Any bleeding leading to relaparotomy or intervention.
Sepsis Presence of two or more of the following: fever or hypothermia, leucocytosis or leucopenia, tachycardia, and
tachypnea or a supernormal minute ventilation.
Intra-abdominal abscesses Intra-abdominal fluid collection with positive cultures identified by ultrasonography or CT, associated with
persistent fever and elevations of white blood cells.
Burst abdomen Post-operative separation of the abdominal musculo-aponeurotic layers with protruding viscera.
Pneumonia Combination of clinical signs (coughing, dyspnoea), with infiltrative abnormalities on chest X-ray, raised
inflammatory parameters (WBC and CRP) and/or positive culture in sputum. In intubated patient a positive
endotracheal culture is mandatory.
Severe wound infection Infection occurring within 30 days after the operative procedure, and requiring hospitalization or intervention
with subsequent prolonged hospital stay (otherwise considered as minor complication).
Severe delayed gastric emptying Persistent need for nasogastric intubation of over 10 days or inability to tolerate solid diet on or after the 14th
postoperative day.
CT: computed tomography. WBC: white blood cell count. CRP: C-reactive protein.
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account the presence of enlarged pancreatic head (not
enlarged pancreatic head (< 4 cm) versus enlarged pan-
creatic head (≥ 4 cm)).
Blinding
Due to the nature of the intervention, blinding of either
patients or treating physicians is not feasible. To ensure
reliability, all outcomes will be cross checked with data
from primary sources by an independent investigator
not involved in patient care and not involved in data
analysis. In case of uncertainty about the definition of an
outcome (e.g. complications), an independent adjudica-
tion committee will perform a blinded outcome assess-
ment of that outcome variable in all patients.
Follow-up and data collection
Izbicki pain score
The Izbicki pain score will be assessed every two weeks
during a follow-up period of 18 months. For this end, the
Izbicki pain score will be assessed via a web questionnaire.Patients who do not have an email will be given a folder
with Izbiki pain score forms and return envelops. Patients
will be contacted by telephone every two weeks and
reminded to fill in the questionnaire and send it to the
trial coordinators. The Izbicki pain score is a one page
questionnaire, easily completed in less than 3 minutes.
The folder with the Izbicki score forms will be re-filled at
every outpatient clinic visit (scheduled every 6 months).
Data sets
A standardized case record form (CRF) will be used. A
study nurse, not involved in patient care, will monitor
the CRFs at all sites. Once a year a minimum of 10% of
the CRF data, including the primary and secondary end-
points, will be verified with source data.
Outpatient follow-up visits
Other outcomes will be collected during scheduled visits
to the outpatient clinic at baseline and at intervals of
6 months for the duration of the study period.
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investigations, as outlined in the ‘Outcomes measures’
section, will be performed at each follow-up visit. Ques-
tionnaires will be mailed prior to follow-up visits and
collected during the visits. The questionnaires will be
processed by medical research staff that is unaware of
the allocated treatment.
Other data
Additionally, relevant data will be collected regarding
any hospital admissions or interventions during the
study period. Interventions encompass all surgical and
endoscopic procedures (including initial surgery), place-
ment of jejunal feeding tubes and nerve blocks.
Sample size
The hypothesis of the study is that early surgery will re-
sult in an early and persistent reduction of pain com-
plaints during the 18 months follow-up. Since pain is
associated with many of the negative effects of CP on
costs, social functioning and quality of life, the average
reduction of pain during this period is of interest.
Calculation of a sample size based on the hypothesized
difference between treatment arms was not possible due
to unavailability of such data. We, therefore, decided to
base this calculation on detecting the minimal clinically
relevant difference of the Izbicki pain score. In a consen-
sus meeting the Chronic Pancreatitis Expert Panel agreed
that the trial should aim to detect a difference of 15 points
or more on the Izbicki pain score (minimal clinically rele-
vant difference) during follow-up. Attempting to detect
smaller differences would not bring any clear advantage to
the clinical decision making process, but would substan-
tially increase the required sample size.
In previous studies, the average within group standard
deviation of the Izbicki pain score was in the order of 20
points. Based on these assumptions, it was determined
that 39 patients per group are needed to detect the min-
imal clinically relevant difference of 15 points on average
using an ‘area under the curve’-analysis, based on alpha
of 0.05 with a power of 90%. Taking into account a
drop-out of 10%, a total sample size of 88 patients will
randomized.
Safety monitoring
An independent data and safety monitoring committee
unaware of treatment assignment will evaluate the pro-
gress of the trial and will examine safety parameters at
regular intervals (60 days after randomization of every
25 patients). All involved physicians will repetitively be
asked to report any potential adverse events during the
study period. These adverse events will be listed and
discussed with the monitoring committee. The monitor-
ing committee can ask for a full report in order todiscuss a specific adverse event. The outcome of the
meeting of the monitoring committee will be sent to the
ethics board and the physicians involved. Any mortality
will be directly reported to the safety committee and
evaluated for cause of death and possible trial related
serious adverse events. All serious adverse events will be
reported online to the Central Committee on Research
involving Human Subjects. Any death will also be
reported to the central ethics board and to the local
ethics board.
Data and statistical analysis
Figure 4 depicts the pre-trial CONSORT diagram. The
primary outcome of the study, the Izbicki pain scores with
2 weeks intervals during follow-up of 18 months, will be
analyzed using an ‘area under the curve’ analysis. This
allows for quantifying and comparing of the effect of study
interventions on pain during the full follow-up period.
Since we will measure the Izbicki pain score at fixed inter-
vals, the ‘area under the curve’ analysis is statistically
equivalent to comparing the average Izbicki score during
the study period. For single missing values, linear
interpolation will be used to impute this missing value. In
case of lost-to-follow-up or drop-out, only the observed
values will be used for analysis (no interpolation will be
used). Secondary outcomes will be compared at the end of
the follow-up. A predefined subgroup analysis in patients
with chronic (continuous) pancreatitis pain and patients
with recurrent pancreatitis flare-ups will be performed.
Analysis of primary and secondary outcomes will be
conducted by a statistician blinded for the treatment al-
location and not involved in data collection. Comparison
of dichotomous outcomes will be performed using the
Chi-squared test or Fisher’s exact test where appropriate.
Results will be presented as number and percentages of
events, as well as relative risk ratios with 95% confidence
interval. For comparing continuous outcomes between
two groups the Students t-test or the Mann-Whitney U
test will be used, depending on the normality of the
sample distribution as tested by the Kolmogorov-
Smirnov test. A two-tailed P < 0.05 will be considered
statistically significant. All analyses will be presented
with 95% confidence intervals. If despite randomization
baseline differences between the two groups were
present, a sensitivity analysis using a multivariate regres-
sion approach will be performed correcting for any
skewed baseline findings. Data will be analyzed on an
intention-to-treat basis.
Ethic and informed consent
The study will be conducted in accordance with the prin-
ciples of the Declaration of Helsinki, and according to the
laws governing human research in the Netherlands and
Good Clinical Practice. The internal review board (IRB) of
Screened for eligibility by trial 
coordinator and physician (n=..) 
Not meeting inclusion criteria or 
meeting exclusion criteria (n=..) 
Refused to participate (n=..) 
To be followed for randomization 
criteria (n=..) 
Not meeting randomization criteria 
(n=..) 
Refused randomization (n=..) 
Excluded for other reasons (n=..) 
To be randomized (n=88) 
To be allocated to intervention (n=..) 
- Projected to not receive allocated 
intervention (n=..) 
Patients with complete data (n=..) 
To be allocated to intervention (n=..) 
- Projected to not receive allocated 
intervention (n=..) 
Patients with complete data (n=..) 
To Receive allocated intervention (n=..) 
- Projected be lost to follow-up (n=..) 
To Receive allocated intervention (n=..) 
- Projected be lost to follow-up (n=..) 
Figure 4 Pre-trial CONSORT chart of the ESCAPE trial.
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protocol. Secondary approval was obtained from the
ethics committees of each participating hospital prior
to commencement of randomization at the respective
hospital. Informed consent will be obtained from each
participating patient in oral and written form prior to
randomization.
Discussion
Relevance of the study
The ESCAPE-trial is a multicenter trial designed to an-
swer the question of whether early surgical interventionfor CP will lead to better pain control and pancreatic
function compared to the current step-up practice. Re-
views and experts have repeatedly indicated a lack of
randomized studies comparing surgical to medical treat-
ment in CP [5,27]. This is widely considered as an im-
portant hiatus in the current knowledge regarding
treatment of this disease. The ESCAPE-trial has, there-
fore, the potential to substantially improve the health
status of CP patients and thereby impact daily clinical
practice. The importance of the ESCAPE-trial is also
strengthened by several reports indicating a substantial
increase in incidence of CP in recent years [28,29].
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As described in the introduction, medical management
is currently the first treatment for many CP patients. Al-
though medical management may suffice to suppress
symptoms early in the disease, it does little to influence
the progression of disease and does not guarantee long-
term relief of symptoms. Longitudinal studies show that
of all CP patients, 40 to 75% will still require surgery for
pain in the course of the disease [3,8,30,31]. The per-
centage of patients requiring a surgical intervention is
probably even higher if only patients that are suitable
candidates for surgery (have morphological abnormal-
ities) are considered.
The current expectative management of CP means
that, even in patients with clear morphological changes,
progression of disease to the extent of severe and debili-
tating pain is a necessity before surgical interventions
are considered. This approach should be questioned in
the light of the prior discussed evidence (see introduc-
tion) suggesting that early intervention could mitigate
disease progression and benefit the patient in terms of
pain control as well as preservation of pancreatic func-
tion. The ESCAPE trial allows to examine these poten-
tial benefits in a setting of a well designed, sufficiently
powered randomized trial.
Rationale for used value of minimal clinically relevant
difference
Calculation of a sample size based on the hypothesized
difference between treatment arms was not possible,
because the anticipated difference in the Izbicki pain
scores between the early surgery group and the optimal
current step-up practice could not be estimated with
precision. Earlier surgical studies only provided Izbicki
pain scores for patients who are operated late in the
disease process. These scores do not reflect the
expected results after early surgery, since we hypothe-
sized that early surgery will achieve better pain control.
In addition, the optimal current step-up practice is a
consensus treatment designed for the purpose of this
study. No exact levels of Izbicki scores are known for
this research arm. The one small RCT by Nealon et al.
that has studied the topic of early surgery in chronic
pancreatitis only presented pain as proportion of pa-
tients with pain relief (94% for the early surgical group
versus 13% for the non-surgical group) [13,15]. We
choose not to use these values for our sample size cal-
culations for several reasons:
– Measuring the outcome continuously best serves
our hypothesis. It enables us to describe and better
quantify the degree of pain during the 1.5 year
follow-up period, and thus relate the degree of pain
with costs and quality of life more precisely.– The non-surgical arm in the above mentioned trial
was not clearly described. In the ESCAPE-trial we
optimized the management of those patients with
our current practice step-approach.
– The observed differences in the trial are very large
whereas its sample size is very small and no formal
sample size calculation had been made; this needs
confirmation in a large trial.
To be able to make a reliable sample size calculation
we, therefore, decided to base this calculation on
detecting the minimal clinically relevant difference in
the average Izbicki pain scores between the two study
groups. This is a recognized and well accepted method
for sample size calculations [32,33]. First, we estimated
the expected Izbicki pain score for the early surgery
group. The most reliable Izbicki pain scores for the
Dutch situation are produced by the CEPAN study
which compared (late) surgery versus endoscopic inter-
vention for CP [17]. The mean Izbicki pain score in the
surgical group was 25 points. For the ESCAPE trial we
hypothesize that an early surgical intervention will be
able to achieve better pain control after surgery; prob-
ably in the range of 10 to 20 points. Subsequently, the
clinical impact of an increase in the Izbicki pain score
from this level by various amounts was discussed. A dif-
ference of 15 points was chosen to be the minimal dif-
ference that would alter the clinical situation of the
patient in a potentially clinically relevant way. For illus-
tration, the clinical meaning of such an increase is
discussed: According to the Izbicki pain score, a patient
with 15 points will have no pain to very mild pain (VAS
1 to 2), that occurs infrequently (several times a year),
will not be in need for opioids medication and the dis-
ease will have minimal effect on the ability to work (no
interfering to about 1 week per year of work disability).
If the Izbicki pain score increases by 15 points (to 30
points) the situation of the patient will change slightly to
the following: the patient will have mild pain (VAS 2.5
to 3.5), with a frequency of about once a month, necessi-
tating weak opioids and interfering slightly with ability
to work (about 1 week per year of work disability).
Powering the trial to detect a smaller difference will in-
crease the sample size substantially without affecting de-
cision making, since smaller differences are likely not
sufficient to change treatment choice from favouring
step-up practice into favouring early surgery.
Rationale for registration prior to randomization
In this trial, we aimed to select patients for which the
two intervention arms are applicable in clinical practice.
If patients can be managed satisfactory with non-opioid
medication, there is no reason to seek more advanced
treatment options. The low risks associated with non-
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justify a change of practice to more advanced modal-
ities like early surgery. Progression of pain toward the
need for opioid analgesics is a clear sign that pain man-
agement of a patient has become complex. We have,
therefore, chosen this event as the most appropriate
moment for randomization. Additionally, newly devel-
oped need for opioids is a transparent clinical event,
thereby increasing the generalizability of the results to
clinical practice.
The expert panel
An Expert Panel of CP specialists (gastroenterologists,
surgeons, pain specialists and radiologists) will over-
see the assessment of eligibility and will ensure that
allocation to either treatment arm is possible prior to
randomization. The expert panel consists of 18 ex-
perts (8 surgeons, 7 gastroenterologists 2 anesthesiol-
ogists and 1 radiologists). The Expert Panel is already
in use within the CARE project, a nationwide pro-
spective registration and follow-up system for CP pa-
tients. Furthermore, the Expert Panel has already
proven to be valuable and highly supportive during
previous trial of the Dutch Pancreatitis Study Group
[34-36].
Formulation of the optimal current step-up practice arm
The current step-up practice arm represents optimal
current practice in the management of chronic pancrea-
titis in the Netherlands. It is in concordance with inter-
national guidelines and current knowledge, and
represents consensus of CP specialists within the Dutch
Pancreatitis Study Group [6,7]. This optimal current
step-up practice according to an explicit consensus
protocol is considered the best alternative available for
comparison to early surgery. An unstandardized control
arm, leaving management decisions at the discretion of
individual physicians is not preferred. From a clinical
point of view it will be hard to know which treatment is
compared in the trial. This will get in the way of drawing
reliable conclusions and reduces the generalizability of
the results.
Few published data exist about the proportion of pa-
tients that in current practice undergo surgery early in
the disease. In a Dutch surgical cohort we observed
that the median time between reported onset of first
pain and endoscopic intervention was 16 months
(10th - 90th percentile 2 to 56), while it took a median
time of 15 months (10th-90th percentile 4 to 81) between
first endoscopic treatment and surgical intervention [37].
In the same cohort patients underwent 0 to up to 29
endoscopic interventions before surgery [37]. In this
trial endoscopic treatment is limited to 12 weeks if
pain persists.Conclusion
The ESCAPE is a randomized controlled multicenter
trial aiming to evaluate the benefits, risks and costs of
early surgical intervention in patients with chronic pan-
creatitis as an alternative to current step-up practice of
pain medication, if needed followed by endoscopic treat-
ment, and eventually if needed followed by surgery.
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